Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Arsenault BJ, Petrides F, Tabet F, Bao W, Hovingh GK, Boekholdt SM, Ramin-Mangata S, Meilhac O, DeMicco D, Rye KA, Waters DD, Kastelein JJP, Barter P, Lambert G. Arsenault BJ, et al. J Clin Lipidol. 2018 Jan-Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12. J Clin Lipidol. 2018. PMID: 29103916 Clinical Trial.
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).
Ho JE, Waters DD, Kean A, Wilson DJ, Demicco DA, Breazna A, Wun CC, Deedwania PC, Khush KK; TNT Investigators. Ho JE, et al. Among authors: demicco da. Am J Cardiol. 2012 Jun 15;109(12):1761-6. doi: 10.1016/j.amjcard.2012.02.019. Epub 2012 Mar 28. Am J Cardiol. 2012. PMID: 22459310 Free PMC article. Clinical Trial.
Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.
Huijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, Tabet F, Petrides F, Rye KA, DeMicco DA, Barter PJ, Kastelein JJ, Lambert G. Huijgen R, et al. Among authors: demicco da. J Am Coll Cardiol. 2012 May 15;59(20):1778-84. doi: 10.1016/j.jacc.2011.12.043. J Am Coll Cardiol. 2012. Retraction in: J Am Coll Cardiol. 2013 Apr 23;61(16):1751. doi: 10.1016/j.jacc.2013.04.002 PMID: 22575316 Free article. Retracted. Clinical Trial.
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL).
Arsenault BJ, Boekholdt SM, Mora S, DeMicco DA, Bao W, Tardif JC, Amarenco P, Pedersen T, Barter P, Waters DD. Arsenault BJ, et al. Among authors: demicco da. Am J Cardiol. 2014 Apr 15;113(8):1378-82. doi: 10.1016/j.amjcard.2014.01.414. Epub 2014 Feb 1. Am J Cardiol. 2014. PMID: 24582532 Clinical Trial.
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
Bangalore S, Fayyad R, Hovingh GK, Laskey R, Vogt L, DeMicco DA, Waters DD; Treating to New Targets Steering Committee and Investigators. Bangalore S, et al. Among authors: demicco da. Am J Cardiol. 2014 Jun 15;113(12):2018-20. doi: 10.1016/j.amjcard.2014.03.046. Epub 2014 Apr 3. Am J Cardiol. 2014. PMID: 24793673 Review.
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ. Boekholdt SM, et al. Among authors: demicco da. J Am Coll Cardiol. 2014 Aug 5;64(5):485-94. doi: 10.1016/j.jacc.2014.02.615. J Am Coll Cardiol. 2014. PMID: 25082583 Free PMC article. Review.
64 results